Pulmonary Arterial Hypertension (pah) Clinical Trials
8 recruiting trials for Pulmonary Arterial Hypertension (pah). Eligibility criteria explained in plain English.
TrialFinderData lists 8 Pulmonary Arterial Hypertension (pah) clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 1 is the largest group at 50% (1 studies); the largest phase groups are Phase 1: 1, Phase 4: 1.
Research is led by University of Sao Paulo General Hospital (3), Joseph C. Wu (1), Second Affiliated Hospital, School of Medicine, Zhejiang University (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Artesunate (drug, 1 trial), followed by Tadalafil, Ambrisentan.
Track Pulmonary Arterial Hypertension (pah) trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension
This is a 20-week, Phase 1, single-center, open-label, dose-escalation study evaluating the safety and tolerability of daily oral artesunate in patients with PAH.
Comparison of Sequential to Initial Combination Therapy in PAH
This is a multicenter, randomized, controlled, double-blind, and non-inferiority clinical trial to compare the efficacy of sequential to initial combination therapy in patients...
AIRDROP: Can we Improve Adherence to Inhaled Treatment for Pulmonary Arterial Hypertension?
Pulmonary Arterial Hypertension is a rare and progressive condition that compromises pulmonary circulation and can lead to right ventricular failure. Despite recent advances in...
Validation of a Patient Knowledge Questionnaire for Pulmonary Hypertension
This methodological study aims to develop and validate a questionnaire named for the Assessment of Patient Knowledge in Pulmonary Arterial Hypertension. The study will be...
COMPERA / COMPERA-KIDS
In view of the manifold options for mono- and combination therapy that have now emerged for patients with pulmonary (arterial) hypertension (PH/PAH), controlled clinical trials...
Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the...
Pulmonary arterial hypertension (PAH) is a progressive disease characterized by vascular remodelling resulting in elevated pressures in the pulmonary artery (PA). This elevated...
PulmonAry hyperteNsion DiagnOsis: a National cohoRt reseArch
Understanding Delays in the Diagnosis of Pulmonary Arterial Hypertension and Rare Diseases in Brazil: A Multicenter Observational Study \--- Pulmonary arterial hypertension (PAH)...
PROOF OF CONCEPT STUDY ON THE EFFICACY OF INHALATORY TARGETED IMATINIB NANOFORMULATIONS IN PULMONARY HYPERTENSION AND...
The PROMPTLY study is a proof-of-concept research project evaluating the efficacy of XHALIP, an innovative inhalable formulation of Imatinib, in treating pulmonary arterial...
Explore Other Conditions
Frequently Asked Questions
There are currently 8 clinical trials for Pulmonary Arterial Hypertension (pah), with 8 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Pulmonary Arterial Hypertension (pah), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Pulmonary Arterial Hypertension (pah), representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.